| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
19,370,000 |
| Market
Cap: |
776.74(K) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.0401 - $1.8 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Aravive is a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of diseases, including cancer and fibrosis. Co.'s primary product candidate, batiraxcept, is a decoy protein that targets the GAS6-AXL signaling pathway. By capturing serum GAS6, batiraxcept starves the AXL pathway of its signal, potentially halting the biological programming that promotes disease progression. AXL receptor signaling plays a role in multiple types of malignancies by promoting metastasis, cancer cell survival, resistance to treatments, and immune suppression.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Zhang Eric |
Director |
• • – |
2022-10-24 |
4/A |
A |
$0.92 |
$500,000 |
I/I |
543,537 |
1,403,303 |
|
- |
|
| Ho Peter Tai-Ching |
Director |
• • – |
2022-10-24 |
4/A |
A |
$0.92 |
$49,999 |
I/I |
54,353 |
55,353 |
|
- |
|
| Ho Peter Tai-Ching |
Director |
• • – |
2022-10-24 |
4 |
A |
$0.92 |
$49,999 |
D/D |
54,353 |
55,353 |
|
- |
|
| Howard Rudy |
Chief Financial Officer |
• • – |
2022-10-24 |
4 |
A |
$0.92 |
$9,999 |
D/D |
10,870 |
10,870 |
|
- |
|
| Mcintyre Gail Frances |
CEO and President |
• • – |
2022-10-24 |
4 |
A |
$0.92 |
$49,999 |
D/D |
54,353 |
65,490 |
|
- |
|
| Giaccia Amato |
Director |
• • – |
2022-10-24 |
4 |
A |
$0.92 |
$249,999 |
D/D |
271,768 |
1,213,648 |
|
- |
|
| Eshelman Ventures, Llc |
Executive Chairman |
• • • |
2022-10-24 |
4 |
A |
$0.92 |
$15,000,000 |
I/I |
16,306,120 |
25,517,889 |
|
- |
|
| Zhang Eric |
Director |
• • – |
2022-10-24 |
4 |
A |
$0.92 |
$500,000 |
D/D |
543,537 |
1,403,303 |
|
- |
|
| Eshelman Ventures, Llc |
Executive Chairman of BoardSee |
• • • |
2022-04-01 |
4 |
OE |
$0.00 |
$455 |
I/I |
4,545,455 |
9,211,769 |
|
- |
|
| Eshelman Ventures, Llc |
Executive Chairman of Board |
• • • |
2022-03-29 |
4 |
A |
$2.33 |
$2,000,002 |
I/I |
860,216 |
4,666,314 |
|
- |
|
| Giaccia Amato |
Director |
• • – |
2021-12-03 |
4 |
GD |
$0.00 |
$0 |
D/D |
48,366 |
941,880 |
|
- |
|
| Shah Vinay |
Chief Financial Officer |
• • – |
2021-06-29 |
4 |
B |
$5.31 |
$5,310 |
D/D |
1,000 |
190,842 |
2.74 |
-27% |
|
| Mcintyre Gail Frances |
CEO and President |
• • – |
2021-06-29 |
4 |
B |
$5.35 |
$5,345 |
D/D |
1,000 |
11,137 |
2.81 |
-27% |
|
| Ho Peter Tai-Ching |
Director |
– • – |
2021-05-12 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,000 |
|
-13% |
|
| Giaccia Amato |
Director |
– • – |
2021-03-19 |
4 |
GD |
$0.00 |
$0 |
D/D |
12,083 |
941,880 |
|
- |
|
| Giaccia Amato |
Director |
– • – |
2021-03-19 |
4 |
OE |
$0.06 |
$725 |
D/D |
12,083 |
953,963 |
|
- |
|
| Eshelman Ventures, Llc |
See Footnote (1) |
– – • |
2021-02-12 |
4 |
A |
$7.29 |
$20,958,750 |
I/I |
2,875,000 |
3,806,098 |
|
- |
|
| Shah Vinay |
Chief Financial Officer |
• – – |
2020-12-04 |
4 |
B |
$5.76 |
$46,080 |
D/D |
8,000 |
189,842 |
2.74 |
-10% |
|
| Mcintyre Gail Frances |
CEO and President |
• • – |
2020-12-04 |
4 |
B |
$5.77 |
$46,160 |
D/D |
8,000 |
10,137 |
2.81 |
-10% |
|
| Eshelman Ventures, Llc |
Director |
– • – |
2020-04-08 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
931,098 |
|
5% |
|
| Hemrajani Rekha |
See Remarks |
– – – |
2020-04-08 |
4 |
D |
$0.00 |
$0 |
D/D |
(42,750) |
14,250 |
|
- |
|
| Shepard Jay |
Former Director |
– – – |
2020-04-08 |
4 |
D |
$0.00 |
$0 |
D/D |
(9,291) |
61,201 |
|
- |
|
| Hemrajani Rekha |
President and CEO |
• • – |
2020-01-09 |
4 |
A |
$0.00 |
$0 |
D/D |
57,000 |
57,000 |
|
- |
|
| Shepard Jay |
President and CEO |
• • – |
2019-12-20 |
4 |
D |
$11.67 |
$26,398 |
D/D |
(2,262) |
70,492 |
|
- |
|
| Akkaraju Srinivas |
Director |
– • – |
2019-12-02 |
4 |
B |
$7.50 |
$999,998 |
I/I |
133,333 |
576,066 |
2.1 |
- |
|
258 Records found
|
|
Page 1 of 11 |
|
|
